Abstract
(Abstracted from N Engl J Med 2023;388(23):2159–2170) Endometrial cancer is one of the only cancer types for which both incidence and mortality are rising, and survival has not improved during the past 4 decades. First-line treatment for advanced or recurrent endometrial cancer typically involves paclitaxel plus carboplatin.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
